Citrus aurantium increases seizure latency to PTZ induced seizures in zebrafish thru NMDA and mGluR's I and II

Frontiers in Pharmacology

Volumn 6, Issue FEB, 2015, Pages

  Rosa Falero, Coral ^a   Torres Rodríguez, Stephanie ^a   Jordán, Claudia ^a   Licier, Rígel ^a   Santiago, Yolimar ^a   Toledo, Zuleyma ^a   Santiago, Marely ^a   Serrano, Kiara ^a   Sosa, Jeffrey ^b   Ortiz, José G ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b Universidad del Este   (United States)

Author keywords

Citrus aurantium; Epilepsy; Glutamate; Natural products; Puerto rican folklore; Zebrafish

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 4 AMINOBUTYRIC ACID A RECEPTOR; CHALCONE DERIVATIVE; GLUTAMIC ACID; HESPERIDIN; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEOHESPERIDIN; NEOHESPERIDIN DIHYDROCHALCONE; PENTETRAZOLE; SOUR ORANGE EXTRACT; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; FEMALE; LATENT PERIOD; LIGAND BINDING; MALE; NONHUMAN; PLANT LEAF; SEIZURE; SEIZURE THRESHOLD; ZEBRA FISH;

EID: 84926508079     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00284     Document Type: Article

References (45)

1. Alvarado-Guzmán, J. A., Gavillán-Suárez, J., and Germosén-Robineau, L. (2009). TRAMIL ethnopharmacological survey: knowledge distribution of medicinal plant use in the southeast region of Puerto Rico. P. R. Health Sci. J. 28, 329-339.
2. Ameer, B., Weintraub, R. A., Johnson, J. V., Yost, R. A., and Rouseff, R. L. (1996). Flavanone absorption after naringin, hesperidin, and citrus administration. Clin. Pharmacol. Ther. 60, 34-40. doi: 10.1016/S0009-9236(96)90164-2
3. Bradford, H. F. (1995). Glutamate, GABA and epilepsy. Prog. Neurobiol. 47, 477-511. doi: 10.1016/0301-0082(95)00030-5
4. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254. doi: 10.1016/0003-2697(76)90527-3
5. Carvalho-Freitas, M. I. R., and Costa, M. (2002). Anxiolytic and sedative effects of extracts and essential oil from Citrus aurantium L. Biol. Pharm. Bull. 25, 1629-1633. doi: 10.1248/bpb.25.1629
6. Castillo, J., Benavente, O., and Del Río, J. A. (1992). Naringin and neohesperidin levels during development of leaves, flower buds, and fruits of Citrus aurantium. Plant Physiol. 99, 67-73. doi: 10.1104/pp.99.1.67
7. Chanet, A., Milenkovic, D., Manach, C., Mazur, A., and Morand, C. (2012). Citrus flavanones: what is their role in cardiovascular protection? J. Agric. Food Chem. 60, 8809-8822. doi: 10.1021/jf300669s
8. Chapman, A. G. (2000). Glutamate and epilepsy. J. Nutr. 130, 1043S-1045S.
9. Chuang, Y.-C. (2010). Mitochondrial dysfunction and oxidative stress in seizure-induced neuronal cell death. Acta Neurol. Taiwan. 19, 3-15.
10. Cramer, J. A., Mintzer, S., Wheless, J., and Mattson, R. H. (2010). Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev. Neurother. 10, 885-891. doi: 10.1586/ern.10.71
11. Del Valle-Mojica, L. M., Ayala-Marín, Y. M., Ortiz-Sanchez, C. M., Torres-Hernández, B. A., Abdalla-Mukhaimer, S., and Ortiz, J. G. (2011). Selective interactions of valeriana officinalis extracts and valerenic acid with [H]Glutamate binding to rat synaptic membranes. Evid. Based Complement. Alternat. Med. 2011, 403591. doi: 10.1155/2011/403591
12. Dias, D. A., Urban, S., and Roessner, U. (2012). A historical overview of natural products in drug discovery. Metabolites 2, 303-336. doi: 10.3390/metabo2020303
13. Fugh-Berman, A., and Myers, A. (2004). Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research adriane. Exp. Biol. Med. 229, 698-704. doi: 10.5812/ircmj.18371
14. Golechha, M., Chaudhry, U., Bhatia, J., Saluja, D., and Arya, D. S. (2011). Naringin protects against kainic acid-induced status epilepticus in rats: evidence for an antioxidant, anti-inflammatory and neuroprotective intervention. Biol. Pharm. Bull. 34, 360-365. doi: 10.1248/bpb.34.360
15. Hamdan, D. I., Mahmoud, M. F., Wink, M., and El-Shazly, A. M. (2014). Effect of hesperidin and neohesperidin from bittersweet orange (Citrus aurantium var. bigaradia) peel on indomethacin-induced peptic ulcers in rats. Environ. Toxicol. Pharmacol. 37, 907-915. doi: 10.1016/j.etap.2014.03.006
16. Harris, P. E., Cooper, K. L., Relton, C., and Thomas, K. J. (2012). Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int. J. Ciln. Pract. 66, 924-939. doi: 10.1111/j.1742-1241.2012.02945.x
17. Hernández, L., Muñoz, R. A., Miró, G., Martínez, M., Silva-Parra, J., and Chávez, P. I. (1984). Use of medicinal plants by ambulatry patients in Puerto Rico. Am. J. Hosp. Pharm. 41, 2060-2064.
18. Ho, S.-C., and Kuo, C.-T. (2014). Hesperidin, nobiletin, and tangeretin are collectively responsible for the anti-neuroinflammatory capacity of tangerine peel (Citri reticulatae pericarpium). Food Chem. Toxicol. 71, 176-182. doi: 10.1016/j.fct.2014.06.014
19. Hu, L., Li, L., Xu, D., Xia, X., Pi, R., Xu, D., et al (2014). Protective effects of neohesperidin dihydrochalcone against carbon tetrachloride-induced oxidative damage in vivo and in vitro. Chem. Biol. Interact. 213, 51-59. doi: 10.1016/j.cbi.2014.02.003
20. Jeong, J.-Y., Kwon, H.-B., Ahn, J.-C., Kang, D., Kwon, S.-H., Park, J. A., et al (2008). Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res. Bull. 75, 619-628. doi: 10.1016/j.brainresbull.2007.10.043
21. Kalueff, A. V, Gebhardt, M., Stewart, A. M., Cachat, J. M., Brimmer, M., Chawla, J. S., et al (2013). Towards a comprehensive catalog of zebrafish behavior 1.0 and beyond. Zebrafish 10, 70-86. doi: 10.1089/zeb.2012.0861
22. Kapur, J., and Lothman, E. W. (1990). NMDA receptor activation mediates the loss of GABAergic inhibition induced by recurrent seizures. Epilepsy Res. 5, 103-111. doi: 10.1016/0920-1211(90)90025-Q
23. Karimi, E., Oskoueian, E., Hendra, R., Oskoueian, A., and Jaafar, H. Z. E. (2012). Phenolic compounds characterization and biological activities of Citrus aurantium bloom. Molecules 17, 1203-1218. doi: 10.3390/molecules17021203
24. Kumar, A., Lalitha, S., and Mishra, J. (2013). Possible nitric oxide mechanism in the protective effect of hesperidin against pentylenetetrazole (PTZ)-induced kindling and associated cognitive dysfunction in mice. Epilepsy Behav. 29, 103-111. doi: 10.1016/j.yebeh.2013.06.007
25. Lahlou, M. (2013). The success of natural products in drug discovery. Pharmacol. Pharm. 4, 17-31. doi: 10.4236/pp.2013.43A003
26. Leysen, J. E., Langlois, X., Heylen, L., and Lammertsma, A. A. (2014). Receptors: Binding Assays. Available online at: http://www.springerreference.com/index/chapterdbid/169194
27. Liu, L., Shan, S., Zhang, K., Ning, Z., Lu, X., and Cheng, Y. (2008). Naringenin and hesperetin, two flavonoids derived from Citrus aurantium up-regulate transcription of adiponectin. Phyther. Res. 1403, 1400-1403. doi: 10.1002/ptr.2504
28. Löscher, W., and Schmidt, D. (2006). New horizons in the development of antiepileptic drugs: innovative strategies. Epilepsy Res. 69, 183-272. doi: 10.1016/j.eplepsyres.2006.03.014
29. Majumdar, S., and Srirangam, R. (2009). Solubility, stability, physicochemical characteristics and in vitro ocular tissue permeability of hesperidin: a natural bioflavonoid. Pharm. Res. 26, 1217-1225. doi: 10.1007/s11095-008-9729-6
30. Meyer, A.-C., Dua, T., Ma, J., Saxena, S., and Birbeck, G. (2010). Global disparities in the epilepsy treatment gap: a systematic review. Bull. World Health Organ. 88, 260-266. doi: 10.2471/BLT.09.064147
31. Moldrich, R. X., Chapman, A. G., De Sarro, G., and Meldrum, B. S. (2003). Glutamate metabotropic receptors as targets for drug therapy in epilepsy. Eur. J. Pharmacol. 476, 3-16. doi: 10.1016/S0014-2999(03)02149-6
32. Neuhaus, W., Freidl, M., Szkokan, P., Berger, M., Wirth, M., Winkler, J., et al (2011). Effects of NMDA receptor modulators on a blood-brain barrier in vitro model. Brain Res. 1394, 49-61. doi: 10.1016/j.brainres.2011.04.003
33. Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., et al (2011). Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 60, 1017-1041. doi: 10.1016/j.neuropharm.2010.10.022
34. Ozawa, S., Kamiya, H., and Tsuzuki, K. (1998). Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54, 581-618. doi: 10.1016/S0301-0082(97)00085-3
35. Patsalos, P. N., and Perucca, E. (2003). Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2, 473-481. doi: 10.1016/S1474-4422(03)00483-6
36. Pultrini, A. D. M., Galindo, L. A., and Costa, M. (2006). Effects of the essential oil from Citrus aurantium L. in experimental anxiety models in mice. Life Sci. 78, 1720-1725. doi: 10.1016/j.lfs.2005.08.004
37. Reed, B., and Jennings, M. (2011). Guidance on the Housing and Care of Zebrafish. Southwater: Royal Society for the Prevention of Cruelty to Animals.
38. Reeta, K. H., Mehla, J., Pahuja, M., and Gupta, Y. K. (2011). Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats. Pharmacol. Biochem. Behav. 99, 399-407. doi: 10.1016/j.pbb.2011.05.011
39. Schoepp, D. D., Jane, D. E., and Monn, J. A. (1999). Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38, 1431-1476. doi: 10.1016/S0028-3908(99)00092-1
40. Sudha, K., Rao, A. V., and Rao, A. (2001). Oxidative stress and antioxidants in epilepsy. Clin. Chim. Acta. 303, 19-24. doi: 10.1016/S0009-8981(00)00337-5
41. Ure, J., Baudry, M., and Perassolo, M. (2006). Metabotropic glutamate receptors and epilepsy. J. Neurol. Sci. 247, 1-9. doi: 10.1016/j.jns.2006.03.018
42. Waldbaum, S., and Patel, M. (2010). Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res. 88, 23-45. doi: 10.1016/j.eplepsyres.2009.09.020
43. Wong, K., Stewart, A., Gilder, T., Wu, N., Frank, K., Gaikwad, S., et al (2010). Modeling seizure-related behavioral and endocrine phenotypes in adult zebrafish. Brain Res. 1348, 209-215. doi: 10.1016/j.brainres.2010.06.012
44. Wong, R., Bianchi, R., Taylor, G., and Merlin, L. (1999). Role of glutamate receptors in epilepsy. Adv. Neurol. 79, 685-698.
45. Zbarsky, V., Datla, K. P., Parkar, S., Rai, D. K., Aruoma, O. I., and Dexter, D. T. (2005). Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic. Res. 39, 1119-1125. doi: 10.1080/10715760500233113